
|Videos|July 4, 2021
Dr. Ramasamy discusses investigational oral testosterone treatment
Author(s)Urology Times staff
Ranjith Ramasamy, MD, comments on SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule.
Advertisement
In this video, Ranjith Ramasamy, MD, discusses SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule for which the FDA recently accepted a new drug application. Ramasamy is an associate professor of urology and director of male reproductive medicine and surgery at the University of Miami Miller School of Medicine.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Matthew Galsky, MD, on how EV/pembrolizumab is redefining the MIBC treatment paradigm
2
Published BOND-003 data show durable responses with cretostimogene in NMIBC
3
Pearls & Perspectives: From Prostate Cancer Diagnosis to Patient Advocacy, with Gabe Canales
4
Cretostimogene Grenadenorepvec: Mechanism and Rationale
5












